NGENEBIO CO., LTD. Financials NGeneBio Co., Ltd.
Equities
A354200
KR7354200008
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,965 KRW | -0.50% |
|
-6.38% | -28.69% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 201,381 | 116,027 | 71,664 |
| Enterprise Value (EV) 1 | 184,281 | 92,565 | 60,681 |
| P/E ratio | -23.8 x | -11.8 x | -5.52 x |
| Yield | - | - | - |
| Capitalization / Revenue | 28.1 x | 10.5 x | 16.5 x |
| EV / Revenue | 25.7 x | 8.4 x | 13.9 x |
| EV / EBITDA | -23.9 x | -12.6 x | -5.02 x |
| EV / FCF | - | 15,961,656 x | -5,577,282 x |
| FCF Yield | - | 0% | -0% |
| Price to Book | 5.92 x | 4.6 x | 4.4 x |
| Nbr of stocks (in thousands) | 12,431 | 12,503 | 12,889 |
| Reference price 2 | 16,200 | 9,280 | 5,560 |
| Announcement Date | 23-03-23 | 23-03-23 | 24-03-20 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales 1 | 7,163 | 11,018 | 4,351 |
| EBITDA 1 | -7,702 | -7,325 | -12,081 |
| EBIT 1 | -8,732 | -8,599 | -13,425 |
| Operating Margin | -121.9% | -78.05% | -308.56% |
| Earnings before Tax (EBT) 1 | -8,431 | -9,839 | -13,175 |
| Net income 1 | -8,431 | -9,785 | -12,769 |
| Net margin | -117.7% | -88.82% | -293.48% |
| EPS 2 | -682.0 | -784.2 | -1,007 |
| Free Cash Flow | - | 5,799 | -10,880 |
| FCF margin | - | 52.64% | -250.07% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 23-03-23 | 23-03-23 | 24-03-20 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 17,100 | 23,462 | 10,983 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | 5,799 | -10,880 |
| ROE (net income / shareholders' equity) | - | -33.2% | -61.9% |
| ROA (Net income/ Total Assets) | - | -10.7% | -17% |
| Assets 1 | - | 91,063 | 74,908 |
| Book Value Per Share 2 | 2,735 | 2,020 | 1,264 |
| Cash Flow per Share 2 | 1,311 | 1,988 | 1,495 |
| Capex 1 | 3,023 | 1,029 | 386 |
| Capex / Sales | 42.2% | 9.34% | 8.88% |
| Announcement Date | 23-03-23 | 23-03-23 | 24-03-20 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -28.69% | 37.87M | |
| -1.49% | 12.71B | |
| +0.13% | 8.37B | |
| -1.12% | 5.4B | |
| +20.81% | 5.27B | |
| -0.74% | 4.63B | |
| -54.56% | 3.13B | |
| +24.56% | 2.77B | |
| -8.47% | 2.25B | |
| -1.86% | 1.95B |
- Stock Market
- Equities
- A354200 Stock
- Financials NGeneBio Co., Ltd.